ERBB2 and breast cancer: Similar to our early-stage patient cohort, LINC00355 was downregulated in 480 early-stage breast cancer samples from The Cancer Genome Atlas (TCGA) from multiple breast cancer subtypes (Fig. 2a): triple negative (n = 72), mean FPKM = 0.151, HER2 + (n = 29), mean FPKM = 0.215, luminal A (n = 298), mean FPKM = 0.237, and luminal B (n = 81), mean FPKM = 0.299, and normal tissue (n = 77), mean FPKM = 0.174.